Novo Nordisk emphasised an interpretation of the data, which assumed all subjects in the study adhered to treatment, that gave a weight reduction ... the CEO of Nkarta, to talk about NK cells ...

Novo Nordisk (NVO) shares traded sharply higher in European trading on Friday after the Danish drugmaker said amycretin, one of its novel obesity therapies, caused up to 22% of weight loss over 36 ...

and brushed off fears of the company falling behind Eli Lilly & Co. Details about its next-generation weight loss drugs ...

Novo Nordisk said that patients taking a higher dose of its blockbuster obesity drug Wegovy lost more weight than those on a lower dose without experiencing an increase in side-effects ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk has been one of the chief beneficiaries ... drug that the company hopes will build on the success of flagship weight-loss treatments Wegovy and Ozempic. Like those injections, the ...

The company states: “Novo Nordisk (NVO) announced headline results ... by demonstrating a statistically significant and superior weight loss at week 72 with semaglutide 7.2 mg versus placebo.

Novo Nordisk's GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications.Seana Smith and Brad Smith ...